BioSante Pharmaceuticals, Inc., founded in 1996 and headquartered in the suburbs of Chicago, Illinois, engages in licensing and development of hormone therapy products, focusing on transdermal gels that deliver bioidentical estradiol and testosterone formulations to treat men and women. The company’s lead products include Elestrin™, an FDA-approved patented gel for the treatment of menopausal symptoms in women, marketed in the U.S. by Bradley Pharmaceuticals, Inc.; and LibiGel®, a patented gel for the treatment of female sexual dysfunction (FSD), which is in Phase III trials. Its other products in development include Bio-E/P-Gel for treatment of menopausal symptoms in women; LibiGel-E/T for treatment of female sexual dysfunction in menopausal women; Bio-T-Gel for treatment of hypogonadism, or testosterone deficiency in men; and triple hormone contraceptives.

The company is also engaged in the development of its proprietary calcium phosphate nanotechnology (CaP), primarily for vaccine adjuvants, immune system boosters and drug delivery systems. Its leading CaP product is BioVant, a proprietary adjuvant and delivery technology for vaccines, currently applied for hepatitis B, avian flu and biodefense vaccines for toxins, such as anthrax. Other CaP technology products comprise BioOral, an oral/buccal/intranasal protein delivery system; BioAir, an inhalable protein delivery system; and BioCap, used in the field of aesthetic medicine.

In June, the company completed an $18.3 million private placement to institutional and other accredited investors, selling a total of 3,054,999 shares of common stock at $6.00 per share and issuing warrants to purchase 763,750 shares of common stock at an exercise price of $8.00 per share.

In 2007, BioSante Pharmaceuticals announced that its calcium phosphate (CaP) nanotechnology performs well as a potential wrinkle filler in cosmetic medicine, with results comparable to other injectable fillers, based on a preclinical study performed by Medical Aesthetics Technology Corporation, the company’s aesthetic medicine partner under an exclusive option and license agreement. BioSante Pharmaceutical announced that its calcium phosphate (CaP) nanoparticle-based vaccine adjuvant, BioVant™, has shown positive adjuvanting effects in a preclinical study designed for the development of a dose sparing vaccine against H5N1 avian flu, widely known as bird flu.